Compounds > 5-phenyl-1,3,4-oxadiazole-2-thiol

Page last updated: 2024-12-09

5-phenyl-1,3,4-oxadiazole-2-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-phenyl-1,3,4-oxadiazole-2-thiol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	735254
CHEMBL ID	1164316
SCHEMBL ID	406885
MeSH ID	M0504659

Synonyms (59)

Synonym
HMS1782D17
BB 0243132
MLS000552751
smr000146266
5-phenyl-[1,3,4]oxadiazole-2-thiol
1,3,4-oxadiazole-2(3h)-thione, 5-phenyl-
einecs 221-103-9
1,3,4-oxadiazole-5-thiol, 2-phenyl-
2-fenil-5-mercapto-1,3,4-ossadiazolo [italian]
5-phenyl-1,3,4-oxadiazole-2(3h)-thione
2-phenyl-1,3,4-oxadiazole-5-thiol
5-phenyl-1,3,4-oxadiazole-2-thiol
3004-42-0
STK096362
5-phenyl-1,3,4-oxadiazole-2-thiol, 97%
SR-01000638256-1
STK208514
inchi=1/c8h6n2os/c12-8-10-9-7(11-8)6-4-2-1-3-5-6/h1-5h,(h,10,12)
fohwxvbzgsvugo-uhfffaoysa-
AKOS000116272
AKOS000269137
HMS1666K12
1,3,4-oxadiazole-2-thiol, 5-phenyl-
5-phenyl-3h-1,3,4-oxadiazole-2-thione
bdbm50320726
CHEMBL1164316 ,
NCGC00246482-01
2-fenil-5-mercapto-1,3,4-ossadiazolo
HMS2273I12
CCG-48741
F3099-6031
5-phenyl-1,3,4-oxadiazole-2(3h)-thione (1)
bdbm152484
SCHEMBL406885
5-phenyl-1,3,4-oxadiazaole-2-thiol
2-phenyl-5-mercapto-1,3,4-oxadiazole
phenyl-1,3,4-oxadiazole-2-thiol
5-phenyl-2-mercapto-1,3,4-oxadiazole
pheny-1,3,4-oxadiazole-2-thiol
5-phenyl-1,3,4-oxadiazole-2-thione
6P-050
DTXSID4062773
AF-615/00099026
5-phenyl-1,3,4-oxadiazol-2-yl hydrosulfide
.delta.2-1,3,4-oxadiazoline-5-thione, 2-phenyl-
2-phenyl-1,3,4-oxadiazoline-5-thione
2-phenyl-5-mercaptooxadiazole
2-phenyl-1,3,4--oxadiazol-5-thiol
IWT ,
mfcd00030467
VU0192207-3
J-017746
Q27461580
4oxocyclopentane-1,2-dicarboxylicacid
EN300-03297
D95715
PD119581
Z55879312
1630090-69-5

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (21)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	8.9125	0.0040	23.8416	100.0000	AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	7.0627	0.1409	11.1940	39.8107	AID2451
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	17.7828	0.1778	14.3909	39.8107	AID2147
Luciferase	Photinus pyralis (common eastern firefly)	Potency	21.3313	0.0072	15.7588	89.3584	AID588342
chaperonin-containing TCP-1 beta subunit homolog	Homo sapiens (human)	Potency	50.1187	3.9811	27.7649	39.8107	AID504842
GLS protein	Homo sapiens (human)	Potency	17.7828	0.3548	7.9355	39.8107	AID624170
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	35.4813	0.0112	12.4002	100.0000	AID1030
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	10.0000	0.2818	9.7212	35.4813	AID2326
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	79.4328	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	3.1623	0.0355	20.9770	89.1251	AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	15.8489	0.0018	15.6638	39.8107	AID894
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	29.9349	0.1683	16.4040	67.0158	AID720504
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	112.2020	0.0501	27.0736	89.1251	AID588590
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0041	9.9625	28.1838	AID2675
relaxin receptor 1 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0388	14.3501	43.6206	AID2676
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	10.0000	1.9953	25.5327	50.1187	AID624287
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	11.9047	1.0000	10.4756	28.1838	AID1457; AID901
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polyphenol oxidase 2	Agaricus bisporus	Ki	6.4700	0.0006	3.2883	8.8900	AID488234
Thymidine phosphorylase	Escherichia coli K-12	IC50 (µMol)	50.0000	0.0027	1.7914	6.5000	AID1335973
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Trypsin	Sus scrofa (pig)	AC50	13.2900	3.3400	16.7050	77.2200	AID488789
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Process	via Protein(s)	Taxonomy
DNA damage response	Thymidine phosphorylase	Escherichia coli K-12
pyrimidine nucleobase metabolic process	Thymidine phosphorylase	Escherichia coli K-12
pyrimidine nucleoside metabolic process	Thymidine phosphorylase	Escherichia coli K-12
thymidine metabolic process	Thymidine phosphorylase	Escherichia coli K-12
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Process	via Protein(s)	Taxonomy
1,4-alpha-oligoglucan phosphorylase activity	Thymidine phosphorylase	Escherichia coli K-12
thymidine phosphorylase activity	Thymidine phosphorylase	Escherichia coli K-12
glycosyltransferase activity	Thymidine phosphorylase	Escherichia coli K-12
pentosyltransferase activity	Thymidine phosphorylase	Escherichia coli K-12
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Process	via Protein(s)	Taxonomy
cytosol	Thymidine phosphorylase	Escherichia coli K-12
membrane	Thymidine phosphorylase	Escherichia coli K-12
cytosol	Thymidine phosphorylase	Escherichia coli K-12
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID488234	Inhibition of mashroom tyrosinase	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triazole-5(4H)-thiones, and substituted hydrazides to the dicopper active site.
AID774816	Antioxidant activity assessed as ABTS radical scavenging activity after 6 mins	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Synthesis and antioxidant activity of novel Mannich base of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan.
AID536607	Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by disk diffusion method	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives.
AID774815	Antioxidant activity assessed as ferric ion reducing activity using ferric-TPTZ by measuring concentration of compound with antioxidant capacity equivalent to ferrous sulfate at 0.5 mmol/L by FRAP assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Synthesis and antioxidant activity of novel Mannich base of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan.
AID536608	Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion method	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives.
AID1422726	Drug level in DTT containing buffer treated with 3-((5-Phenyl-1,3,4-oxadiazol-2-yl)thio)benzo[b]thiophene-1,1-dioxide by LC-MS analysis	2018	Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20	Antifungal benzo[b]thiophene 1,1-dioxide IMPDH inhibitors exhibit pan-assay interference (PAINS) profiles.
AID536606	Antimicrobial activity against Escherichia coli MTCC 443 after 24 hrs by disk diffusion method	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives.
AID1335973	Inhibition of Escherichia coli K12 thymidine phosphorylase expressed in Escherichia coli preincubated for 10 mins followed by substrate addition measured up to 30 mins by spectrophotometric method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
AID774817	Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Synthesis and antioxidant activity of novel Mannich base of 1,3,4-oxadiazole derivatives possessing 1,4-benzodioxan.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1801047	Thymidine Phosphorylase Inhibition Assay from Article 10.1016/j.bioorg.2015.04.003: \\Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives.\\	2015	Bioorganic chemistry, Jun, Volume: 60	Synthesis, thymidine phosphorylase inhibition and molecular modeling studies of 1,3,4-oxadiazole-2-thione derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (6.67)	29.6817
2010's	13 (86.67)	24.3611
2020's	1 (6.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.67 (24.57)
Research Supply Index	2.83 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (6.25%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	15 (93.75%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
4-hydroxybenzoic acid hydrazide 4-hydroxybenzoic acid hydrazide: metabolite of nifuroxazide. 4-hydroxybenzohydrazide : A carbohydrazide obtained by formal condensation of the carboxy group of 4-hydroxybenzoic acid with hydrazine.	2.05	1	carbohydrazide; phenols
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.05	1	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	2.17	1	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
kojic acid [no description available]	2.05	1	4-pyranones; enol; primary alcohol	Aspergillus metabolite; EC 1.10.3.1 (catechol oxidase) inhibitor; EC 1.10.3.2 (laccase) inhibitor; EC 1.13.11.24 (quercetin 2,3-dioxygenase) inhibitor; EC 1.14.18.1 (tyrosinase) inhibitor; EC 1.4.3.3 (D-amino-acid oxidase) inhibitor; NF-kappaB inhibitor; skin lightening agent
butylated hydroxytoluene 2,6-di-tert-butyl-4-methylphenol : A member of the class of phenols that is 4-methylphenol substituted by tert-butyl groups at positions 2 and 6.	2.08	1	phenols	antioxidant; ferroptosis inhibitor; food additive; geroprotector
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.08	1	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
6-aminothymine 6-aminothymine: inhibits degradation of nucleosides (idoxuridine, thymidine) & pyrimidine bases	3.23	1
6-amino-5-bromouracil [no description available]	3.23	1
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	2.17	1	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
4-amino-5-(pyridin-4-yl)-4h-1,2,4-triazole-3-thiol 4-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-3-thiol: a ligand of some antineoplastic metal complexes; structure in first source	2.05	1
tamoxifen [no description available]	2.17	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	2.17	1	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride tipiracil hydrochloride : A hydrochloride obtained by combining tipiracil with one equivalent of hydrochloric acid. Used in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer.	3.23	1	hydrochloride; iminium salt	antineoplastic agent; EC 2.4.2.4 (thymidine phosphorylase) inhibitor
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	2.15	1
sesone 7-deazaxanthine: structure in first source	3.62	2

Condition	Relationship Strength	Studies
Hypermelanosis [description not available]	2.05	1
Hyperpigmentation Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	3.04	1
Benign Neoplasms [description not available]	3.04	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.04	1
C gattii Infection [description not available]	2.17	1
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	2.17	1
Bacterial Disease [description not available]	2.15	1
Bacterial Infections Infections by bacteria, general or unspecified.	2.15	1

chemdatabank.com